Cord blood cells can work through paracrine and trophic mechanisms to help endogenous cells heal brain tissue damaged by disease or injury. Learning from observations made using unrelated donor umbilical cord blood transplantation after myeloablative chemotherapy to treat children with certain inherited metabolic diseases, cord blood therapies have been developed to treat children with acquired brain injuries, like hypoxic ischemic encephalopathy, cerebral palsy, and autism. Results of preclinical and IND enabling studies will be presented to provide information about safety and potential mechanisms of action of cord blood cells in this setting. Data from early phase human clinical trials for safety and efficacy in these diseases will be presented by the speaker in this session.